Guardant Health
Develops liquid biopsy blood tests for cancer detection, treatment selection, and monitoring.
What they do
Guardant Health offers non-invasive liquid biopsy tests that detect cancer from tumor DNA in blood samples. Oncology clinics and biopharmaceutical partners use these diagnostics to guide treatment decisions, monitor recurrence, and accelerate clinical trials for advanced-stage cancer patients.
The record
- Vertical
- Oncology
- Sub-segment
- Early cancer detection
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Redwood City, United States
- Region
- North America
- Founded
- 2012
- Total funding
- $550M raised
Notable investors: SoftBank Vision Fund, Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners.